期刊文献+

目标剂量美托洛尔缓释片对慢性心力衰竭患者的影响 被引量:3

Effects of target dose of metoprolol sustained-release tablets on patients with chronic heart failure
下载PDF
导出
摘要 目的探讨目标剂量美托洛尔缓释片对慢性心力衰竭(CHF)患者的影响。方法将210例CHF患者随机分为观察组和对照组,每组105例。在常规心衰治疗基础上,观察组服用目标剂量美托洛尔缓释片,对照组服用固定小剂量美托洛尔缓释片。10个月后,比较2组患者总有效率、左室射血分数(LVEF)、左室收缩末期容积(LVESV)、左室舒张末期容积(LVEDV)、再次住院率及不良事件发生情况,以及治疗前后的静息心率(RHR)、N末端B型脑钠肽(NT-proBNP)、6 min步行距离(6 MWT)的变化。结果观察组患者总有效率显著高于对照组,而再次住院率显著低于对照组,差异均有统计学意义;观察组患者LVEF显著高于对照组,而LVESV及LVEDV显著低于对照组;观察组RHR及NT-proBNP显著低于对照组,而6MWT显著高于对照组。结论目标剂量美托洛尔缓释片能有效提高CHF患者的临床疗效,改善运动耐量,降低再次住院率,改善患者生活质量,其疗效优于固定小剂量。 Objective To tablets on the patients with chronic explore effects of target dose heart failure (CHF). Methods of metoprolol sustained-release Two hundred and ten patients with CHF were randomly divided into observation group and control group, 105 cases in each group. Based on the conventional treatment of heart failure, the observation group was given target dose of metoprolol sustained-release tablets, while the control group given the fixed small dose. Ten months later, the total efficacy rate, left ventricular ejection fraction (LVEF), left ventricular end systolic volume (LVESV), left ventricular end diastolic volume (LVEDV), a second hospitalization rate and adverse reactions as well as the changes of rest heart rate (RHR), N-terminal B-type natriuretic peptide (NT-proBNP) and 6 min walking test (6 MWT) before and after treatment were compared in the two groups. Results The total efficacy rate of the observation group was markedly higher than that of the control group, while the second hospitalization rate obviously lower, the difference having statistical significance. LVEF and 6 MWT of the observation group were evidently higher than that of the control group, while LVESV, LVEDV, RHR and NT-proBNP conspicuously lower. Conclusion The target dose of metoprolol sustained-release tablets can effectively improve the clinical effect of patients with CHF, ameliorate exercise tolerance, decrease a second hos- pitalization rate, enhance the quality of life, and its therapeutic effect is superior to the fixed small dose.
作者 任勇 秦震芳
出处 《实用临床医药杂志》 CAS 2013年第15期66-68,共3页 Journal of Clinical Medicine in Practice
基金 中国高校医学期刊临床专项资金(11321064)
关键词 慢性心力衰竭 目标剂量 美托洛尔缓释片 chronic heart failure, target dose metoprolol sustained-release tablets
  • 相关文献

参考文献13

  • 1Shim S H, Braunwald E, Bristow M R. Congestive heart failure: fifty years of progress[J]. Circulation, 2000, 102 (20 Suppl 4) : IV14.
  • 2Martinez A S, Saef J, Paszczuk A, et ah Implementation of a pharmacist-managed heart failure medication titration clinic [J]. AmJ Health Syst Pharm, 2013, 70(12): 1070.
  • 3Meuwese C L, Kirkels J H, de Jonge N, et ah Beta-blocker therapy in unstable severe heart failure, evidence or experi- ence[J]. Neth Heart J, 2013, 21(1) : 3.
  • 4Sidorenko B A, Preobrazhensky D V, Batyraliev T A, et al. Contemporary approaches to diagnosis and management of chronic heart failure (summary of the American College of Cardiology/American Heart Association Guidelines ) [ J ]. Kardiologiia, 2002, 42(6): 65.
  • 5Bropht J N, Joseph L, Roule.aa J L. Beta-blockers in conges- tive heart failure. A Rayesian meta-analysis[J]. Ann Intern Med, 2001, 134(7): 550.
  • 6Ozasa N, Morimoto T, Bao B, et al. ~-blocker use in pa- tients after pereutaneous coronary interventions: One size fits all? Worse outcomes in patients without myocardial infarction or heart failure[J]. Irlt J Cardiol, 2012, [Epub ahead of print].
  • 7Pocock S J, Ariti C A, McMurray J J, et al. Predicting sur- vival in heart failure: a risk score based on 39 372 patients from 30 studies[J]. Ear Heart J, 2013, 34(19): 1404.
  • 8Syrkin A L, Kukes V G, Poltavskaia M G, et al. Effect of beta-blockers metoprolol CR/XL and carvedilol on left ven- tricular contractility in patients with chronic low cardiac out- put[J]. Ter Arkh, 2003, 75(9): 73.
  • 9Stanek B, Frey B, Hfllsmann M, et al. Prognostic evalua- tion of neurohumoral plasma levels before and during beta- blocker therapy in advanced left ventricular dysfunction[J]. J Am Call Cardiol, 2001, 38(2) : 436.
  • 10钟文娟,陈慧,吴小盈.监测氨基末端脑钠肽前体对心力衰竭患者的预后价值[J].中华高血压杂志,2010,18(1):41-45. 被引量:40

二级参考文献17

  • 1张昀昀,顾水明,薛晓培,张洁,魏盟.伊贝沙坦能改善高血压病人左室肥厚和胰岛素抵抗[J].中华高血压杂志,2006,14(8):664-666. 被引量:8
  • 2Kawai K,Hata K,Takaoka H,et al. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopethy durin8 beta-blocker therapy :a potential of honnoneguided treatment[ J]. Heart, 2001,141(6) :925-932.
  • 3Teutamoto T, Wada A. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure:prognostlc role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction [J ]. Circulation, 997,96 : 509- 516.
  • 4Tulevsld II,Groanink M, Van Der Wall EE ,et al. Increased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure overload :correlation between plasma neurohonnones and right vantricular dysfunction[ J]. Heart,2001,86( 1 ) :27-30.
  • 5Hunt PJ, Riehards AM, Nicholta MG, et al. Immunoreactive amino terminal pro brain natriuretlc peptideta(NT-proBNP) new marker of cardiac impainnent[J]. Clin Endccrinol,1997,47(3) :287-296.
  • 6Jmn SK, Lindahl B, Siegbahn A, et al N-terminal pro brain natriuretie peptide and other risk nmrkers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease;a global utilization of strategies to open occluded arteries (GUSTO) -Iv substudy[ J]. Circulation ,2003,108 (3) :275-281.
  • 7Balion C, Santaguida PL, Hill S, et al. Testing for BNP and NT- proBNP in the diagnosis and prognosis of heart failure[J].Evid Rep Technol Assess(Full Rep), 2006 : 1- 147.
  • 8O'Brien RJ, Squire IB, Demme B, et al. Pre-discharge, but not admission, levels of NT proBNP predict adverse prognosis follow ing acute LVF[J]. Eur J Heart Fail, 2003,5 : 499-506.
  • 9Fonseca C, Sarmento AM, Minez A, et al. Comparative value of BNP and NT-proBNP in diagnosis of heart failure[J]. Rev Port Cardiol,2004,23 :979- 991.
  • 10Serge Masson, Roberto Latini, Inder S. Direct Comparison of B- Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP in a Large Population of Patients with Chronic and Symptomatic Heart Failure:The Valsartan Heart Failure (Val-HeFT)Data[J]. Clinical Chemistry, 2006,52 : 1528-1538.

共引文献40

同被引文献39

二级引证文献250

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部